EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RE‐START : Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine

Celia Romero Del Rincón iD, Alicia Gonzalez-Martinez iD, Sonia Quintas iD, David García-Azorín iD, Iris Fernández Lázaro, Angel Luis Guerrero-Peral iD, Yesica Gonzalez Osorio iD, Sonia Santos-Lasaosa, Carmen González Oria, Norberto Sánchez Rodríguez, Fernando Iglesias Díez, Ana Echavarría Íñiguez iD und 19 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Celia Romero Del Rincón und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma d…. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), European Union and FEDER funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption.

Methods

This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti‐CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti‐CGRP MAb (T‐baseline); last month of first treatment period (T‐suspension); month of restart due to worsening (T‐worsening); and 3 months after resumption (T‐reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD.

Results

A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T‐baseline was 20 (13) and MMD was 5 (6); at T‐suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T‐worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T‐reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period ( p < 0.001).

Conclusion

The results suggest that anti‐CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideMigraine DisordersHumansFemaleAdolescentMaleProspective StudiesHeadacheAntibodies, Monoclonal

Stichwörter der Autor:innen

CGRPeffectivenessmigraineresponseresumption

Substanzen

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurology, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  • Headache Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Department of Medicine, Universidad de Valladolid, Valladolid, Spain.
  • Headache Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Headache Unit, Hospital Virgen del Rocío, Sevilla, Spain.
  • Headache Unit, Hospital Clínico Universitario de Burgos, Burgos, Spain.

ORCID-Profile: Celia Romero Del Rincón, Alicia Gonzalez-Martinez, Sonia Quintas, David García-Azorín, Angel Luis Guerrero-Peral, Yesica Gonzalez Osorio, Ana Echavarría Íñiguez, Mariano Huerta-Villanueva, Sergio Campoy Díaz, Albert Muñoz-Vendrell, Antonio Sánchez-Soblechero, Izaro Kortazar-Zubizarreta, Noemí Morollón Sánchez-Mateos, María Pilar Navarro Pérez, Ana Beatriz Gago-Veiga

Förderung

  • Instituto de Salud Carlos III (ISCIII)
  • European Union and FEDER funds

Zitieren

APA

Romero Del Rincón, C., Gonzalez-Martinez, A., Quintas, S., García-Azorín, D., Fernández Lázaro, I., Guerrero-Peral, A. L., Gonzalez Osorio, Y., Santos-Lasaosa, S., González Oria, C., Sánchez Rodríguez, N., Iglesias Díez, F., Echavarría Íñiguez, A., Gil Luque, S., Huerta-Villanueva, M., Campoy Díaz, S., Muñoz-Vendrell, A., Lozano Ros, A., Sánchez-Soblechero, A., Velasco Juanes, F., …, & Gago-Veiga, A. B. (2024). RE‐START : Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine. European Journal of Neurology. https://doi.org/10.1111/ene.16203

Vancouver

Romero Del Rincón C, Gonzalez-Martinez A, Quintas S, García-Azorín D, Fernández Lázaro I, Guerrero-Peral AL, et al. RE‐START : Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine. European Journal of Neurology. 2024. doi:10.1111/ene.16203

BibTeX
@article{RomeroDelRincn2024,
  author = {Romero Del Rincón, Celia and Gonzalez-Martinez, Alicia and Quintas, Sonia and García-Azorín, David and Fernández Lázaro, Iris and Guerrero-Peral, Angel Luis and Gonzalez Osorio, Yesica and Santos-Lasaosa, Sonia and González Oria, Carmen and Sánchez Rodríguez, Norberto and Iglesias Díez, Fernando and Echavarría Íñiguez, Ana and Gil Luque, Sendoa and Huerta-Villanueva, Mariano and Campoy Díaz, Sergio and Muñoz-Vendrell, Albert and Lozano Ros, Alberto and Sánchez-Soblechero, Antonio and Velasco Juanes, Fernando and Kortazar-Zubizarreta, Izaro and Echeverría, Amaya and Rodríguez-Vico, Jaime and Jaimes Sánchez, Alex and Gómez García, Andrea and Morollón Sánchez-Mateos, Noemí and Belvis, Robert and Navarro Pérez, María Pilar and García-Moncó, Juan Carlos and Álvarez Escudero, María Rocío and Montes, Nuria and Gago-Veiga, Ana Beatriz},
  title = {RE‐START : Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16203}
}
Kostenlos starten →